Aromatase inhibitors and their use in the sequential setting

Endocrine-Related Cancer

Volumn 6, Issue 2, 1999, Pages 259-263

  Coombes, R C ^a   Harper Wynne, C ^b   Dowsett, M ^b  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROSTENEDIONE; AROMATASE; AROMATASE INHIBITOR; CYTOCHROME P450; ESTROGEN RECEPTOR; EXEMESTANE; FOLLITROPIN; FORMESTANE; GOSERELIN; LETROZOLE; LUTEINIZING HORMONE; MEGESTROL ACETATE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; VOROZOLE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME INHIBITION; ESTROGEN BLOOD LEVEL; HOT FLUSH; HUMAN; NAUSEA; POSTMENOPAUSE; RASH; VERTIGO;

ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; TRIAZOLES;

EID: 0033049323     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0060259     Document Type: Article

References (31)

1. Bergh J, Bonneterre J, Illiger HJ, Murray R, Nortier J, Paridaens R, Rubens RD, Samonigg H & Van Zyl J for the Vorozole Study Group 1997 Vorozole (Rivizor) versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen. Proceedings of American Society of Clinical Oncology No. 543.
2. Brodie AMH, Garrett WM, Hendrickson JR, Tsai-Morris CH, Marcotte PA & Robinson CH 1981 Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. Steroids 38 693-702.
3. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P & Webster A for the Arimidex Study Group 1997 A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 79 730-739.
4. Coombes RC, Goss P, Dowsett M, Gazet J-C & Brodie A 1984 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer Lancet 2 1237-1239.
5. Coombes RC, Hughes SWM & Dowsett M 1992 4-Hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer. European Journal of Cancer 28A 1941-1945.
6. Di Salle E, Briatico G, Giudici D, Omati G & Zaccheo T 1989 Aromatase inhibition and experimental antitumour activity of FCE24304 & MDL 18962 and SH489. Journal of Steroid Biochemistry 34 431-434.
7. Di Salle E, Ornati G, Paridaens R, Coombes RC, Lobelle JP & Zurlo MG 1994 Preclinical and clinical pharmacology of the aromatase inhibitor exemestane (FCE 24304). In Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. Eds M Motta & M Serio. Amsterdam: Elsevier Science B.V.
8. Dombernowsky P, Smith I, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Huffman W, Michel J, Hatscheck T, Tjabbes T, Chaudri HA, Hornberger U & Trunet PF 1998 Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology 16 453-461.
9. Dowsett M, Mehta A, King N, Smith IE, Powles TJ, Stein RC & Coombes RC 1992 An endocrine and pharmacokinetic study of 4 oral doses of formestane in post-menopausal breast cancer patients. European Journal of Cancer 28 415-420.
10. Dowsett M, Doody D, Miall S, Howes A, English J & Coombes RC 1999 Vorozole results in greater oestrogen suppression than foremestane in post-menopausal women and when added to goserelin in pre-menopausal women with advanced breast cancer. Breast Cancer Research and Treatment (In Press).
11. Evans RTJ, Di Salle E, Ornati G, Lassus M, Benedetti MS, Pianezzola E & Coombes RC 1992 Phase I and endocrine study of exemestane (FCE24304), a new aromatase inhibitor, in postmenopausal women. Cancer Research 52 5933-5939.
12. Gazet J-C, Coombes RC, Ford HT, Griffin M, Corbishley C, Makinde V, Lowndes S, Quilliam J & Sutcliffe R 1996 Assessment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer. British Journal of Cancer 73 758-762.
13. Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO & Lonning PE 1996 Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. British Journal of Cancer 74 1286-1291.
14. Goss P, Wine E, Tannock I, Schwartz IH & Kremer AB for the North American Vorozole Study Group 1997 Vorozole versus Megace in postmenopausal patients with metastatic breast carcinoma who had relapsed following tamoxifen. Proceedings of American Society of Clinical Oncology No. 542.
15. Harper-Wynne C & Coombes RC 1999 Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy. European Journal of Cancer (In Press).
16. Harris AL, Dowsett M, Smith IE & Jeffcoate SL 1983 Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. British Journal of Cancer 47 621-627.
17. Johnston SRD, Smith IE, Doody D, Jacobs S, Robertshaw H & Dowsett M 1994 Clinical and endocrine effects of the oral aromatase inhibitor Vorozole in postmenopausal patients with advanced breast cancer. Cancer Research 54 5875-5881.
18. Jones AL, MacNeil F, Jacobs S, Lonning PE, Dowsett M & Powles TJ 1992 The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. European Journal of Cancer 28 1712-1716.
19. Lipton A, Demers LM, Harvey HA, Kambic KB, Grossberg H, Brady C, Adkercruetz H, Trunet PF & Santen RJ 1995 Letrozole (CGS20267). A Phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 75 2132-2138.
20. Lonning PE, Jacobs S, Jones A, Haynes B, Powles T & Dowsett M 1991 The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. British Journal of Cancer 63 789-793.
21. Lonning PE, Dowsett M, Jones A, Ekse D, Jacobs S, MacNeill F, Johannessen DC & Powles TJ 1992 Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment. Breast Cancer Research and Treatment 23 57-62.
22. Marty M, Gershanovich M, Campos B, Romieu G, Lurie H, Bonaventura T, Jeffrey M, Buzzi F, Ludwig H, Bodrogi I, Reichardt P, O'Higgins N, Chaudri HA, Friederich P & Biachoff MA for the Letrozole International Trial Group (AR/ BC3) 1997 Letrozole, a new potent selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with anti-estrogens. Proceedings of American Society of Clinical Oncology No. 544.
23. Masamura S, Adlercreutz H, Harvey H, Lipton A, Demers LM, Santen RJ & Santner SJ 1995 Aromatase inhibitor development for treatment for breast cancer. Breast Cancer Research and Treatment 33 19-26.
24. Murray R & Pitt P 1995 Aromatase inhibition with 4-OH-androstenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Research and Treatment 35 249-253.
25. Plourde OV, Dyroff M & Dukes M 1994 Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Research and Treatment 30 103-111.
26. Poon GK, Jarman M, Rowlands MG, Dowsett M & Firth J 1991 Determination of 4-hydroxyandros-4-ene-3,17-dione metabolism in breast cancer patients using HPLC/MS. Journal of Chromatography 565 75-88.
27. Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E & Ruby E 1978 Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. Journal of Clinical Endocrinology and Metabolism 47 1257-1265.
28. Stein RC, Dowsett M, Hedley A & Coombes RC 1990 The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. British Journal of Cancer 62 679-683.
29. Stuart-Harris R, Dowsett M & D'Souza A 1985 Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer. Clinical Endocrinology 22 219-226.
30. Thurlimann B, Paridaens R, Serin D, Bonneterre J, Roche H, Murray R, di Salle E, Lanzalone S, Zurlo MG & Piscitelli G 1997 Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a Phase II multicentre multinational study. European Journal of Cancer 33 1767-1773.
31. Zaccheo T, Giudici D, Ornati G, Panzeri A & Di Salle E 1991 Comparison of the effects of the irreversible aromatase inhibitor, exemestane, with atamestane and MDL 18962 in rats with DMBA-induced mammary tumors. European Journal of Cancer 27 1145-1150.